This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Carlo-Stella, C. Articles by Gianni, A. M. Search for Related Content PubMed PubMed Citation Articles by Carlo-Stella, C. Articles by Gianni, A. M.

IFN- Enhances the Antimyeloma Activity of the Fully Human Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3

¹ "Cristina Gandini" Medical Oncology Unit, ² Experimental Oncology, ³ Hematology and BMT Unit, and ⁴ Pathology, Istituto Nazionale Tumori; ⁵ Medical Oncology, University of Milano, Milan, Italy; and ⁶ GPC Biotech AG, Munich, Germany

Requests for reprints: Carmelo Carlo-Stella, "Cristina Gandini" Medical Oncology Unit, Istituto Nazionale Tumori, Via Venezian, 1, 20133 Milan, Italy. Phone: 39-02-2390-2717; Fax: 39-02-2390-3461; E-mail: carmelo.carlostella{at}unimi.it.

To investigate the therapeutic activity of the fully human anti–HLA-DR antibody 1D09C3 in multiple myeloma (MM), we reevaluated HLA-DR expression on CD138⁺ cells, analyzed the capacity of IFN- to up-regulate HLA-DR expression on MM cell lines, and tested the in vitro and in vivo activity of 1D09C3 alone or in combination with IFN-. CD138⁺HLA-DR⁺ cells were detected in 31 of 60 patients, with 15 of 60 patients having 20% CD138⁺HLA-DR⁺ cells (median, 50%; range, 23–100). Because primary plasma cells cannot be efficiently cultured in vitro, we used a panel of MM cell lines with a dim/negative to bright HLA-DR expression to evaluate 1D09C3-induced cell death. Annexin V/propidium iodide (PI) staining showed that 1D09C3-induced cell death correlated with constitutive HLA-DR expression. Induction of HLA-DR by IFN- restored the sensitivity of HLA-DR dim cell lines to 1D09C3. In vivo, the combined IFN-/1D09C3 treatment significantly increased the median survival of nonobese diabetic/severe combined immunodeficient mice xenografted with KMS-11 cell line, compared with controls (147 versus 48 days, P 0.0001) or mice receiving 1D09C3 alone (147 versus 92 days, P 0.03). The better therapeutic activity of IFN-/1D09C3 treatment over 1D09C3 alone was further shown by a 2-fold increase of mice being disease-free at 150 days after xenograft (47% versus 25%). No mice experienced any apparent treatment-related toxicity. Our data show that (a) one fourth of MM patients express HLA-DR on CD138⁺ cells and (b) IFN-–induced up-regulation of HLA-DR results in a potent enhancement of the in vivo antimyeloma activity of 1D09C3. [Cancer Res 2007;67(7):3269–75]